Login to Your Account

Financings Roundup

'FASN' Your Seat Belt: Series C Funds 3-V Biosciences' Phase I

By Randy Osborne
Staff Writer

Monday, June 24, 2013
3-V Biosciences Inc.'s $20 million Series C financing will push the lead cancer product, a fatty acid synthase (FASN) inhibitor, through Phase I trials, while boosting preclinical studies with leads in virology – the research area on which the company was founded in 2007.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription